Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 04.06
    2022

    Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders

  • 03.31
    2022

    ADDEX CONVENES ANNUAL GENERAL MEETING 2022

  • 03.24
    2022

    Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences

  • 03.10
    2022

    Addex Reports Full Year 2021 Financial Results and Provides Corporate Update

  • 03.07
    2022

    Addex Therapeutics to Release Full-Year 2021 Financial Results and Host Conference Call on March 10, 2022

  • 02.24
    2022

    Addex to Present at the Virtual Sachs Associates 3rd Annual European HealthTech and 15th Annual European Life Sciences CEO Forums

  • 02.03
    2022

    Addex Increases Issued Share Capital to Create Treasury Shares

  • 01.11
    2022

    Addex to Present at the Swiss Equities Baader Virtual Conference

  • 01.06
    2022

    Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

  • 12.17
    2021

    Addex Raises $10.0 Million in Equity Financing

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics